Purpose: To report a retrospective observational analysis of standard balloon angioplasty (BA) vs. paclitaxel-coated balloon angioplasty (PCBA) for symptomatic central vein restenoses in patients with impaired native hemodialysis fistulas. Methods: A retrospective review was conducted of 27 consecutive patients (15 men; mean age 66±13.8 years, range 39–90) with 32 central vein stenoses (CVS; 6 axillary, 11 subclavian, 12 brachiocephalic, and/or 3 superior caval veins) treated successfully using BA. Freedom from reintervention after BA of de novo lesions was 7.4±7.9 months (range 1–24). Twenty-five (92.6%) patients developed symptomatic restenoses and were treated one or more times by BA (n=32) or PCBA (n=20) using custom-made paclitaxel-coated balloons (diameter 6–14 mm). Results: Technical (<30% residual stenosis) and clinical (functional fistula) success rates for the initial and secondary angioplasty procedures were 100%. No minor/major procedure-associated complications occurred. Mean follow-up was 18.4±17.5 months. Kaplan-Meier analysis for freedom from target lesion revascularization (TLR) found PCBA superior to BA (p=0.029). Median freedom from TLR after BA was 5 months; after PCBA, >50% of patients were event-free during the observation period (mean freedom from TLR 10 months). Restenosis intervals were prolonged by PCBA (median 9 months) vs. BA (median 4 months; p=0.023). Conclusion: Paclitaxel-coated balloon angioplasty of central vein restenosis in patients with hemodialysis shunts yields a statistically significant longer freedom from TLR compared to standard balloon angioplasty.
BakerGLBarnesHJ. Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care. 1992;1:54–64.
2.
KhannaSSnidermanKSimonsM. Superior vena cava stenosis associated with hemodialysis catheters. Am J Kidney Dis. 1993;21:278–281.
3.
LumsdenABMacDonaldMJIsiklarH. Central venous stenosis in the hemodialysis patient: incidence and efficacy of endovascular treatment. Cardiovasc Surg. 1997;5:504–509.
4.
GlanzSGordonDHLipkowitzGS. Axillary and subclavian vein stenosis: percutaneous angioplasty. Radiology. 1988;168:371–373.
5.
AsifASalmanLCarrilloRG. Patency rates for angioplasty in the treatment of pacemaker-induced central venous stenosis in hemodialysis patients: results of a multi-center study. Semin Dial. 2009;22:671–676.
6.
ShingarevRBarker-FinkelJAllonM. Association of hemodialysis central venous catheter use with ipsilateral arteriovenous vascular access survival. Am J Kidney Dis. 2012;60:983–989.
7.
VanherweghemJLYassineTGoldmanM. Subclavian vein thrombosis: a frequent complication of subclavian vein cannulation for hemodialysis. Clin Nephrol. 1986;26:235–238.
8.
KotodaAAkimotoTKatoM. Central venous stenosis among hemodialysis patients is often not associated with previous central venous catheters. ASAIO J. 2011;57:439–443.
9.
OguzkurtLTercanFYildirimS. Central venous stenosis in haemodialysis patients without a previous history of catheter placement. Eur J Radiol. 2005;55:237–242.
10.
KellyBSHeffelfingerSCWhitingJF. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int. 2002;62:2272–2280.
11.
LeeTRoy-ChaudhuryP. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 2009;16:329–338.
12.
ShiYYeMLiangW. Endovascular treatment of central venous stenosis and obstruction in hemodialysis patients. Chin Med J (Engl). 2013;126:426–430.
13.
ChangC-JKoP-JHsuL-A. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis. 2004;43:74–84.
14.
SuzukiTKopiaGHayashiS. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–1193.
15.
HeldmanAWChengLJenkinsGM. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289–2295.
16.
MoriceM-CSerruysPWSousaJE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.
17.
StoneGWEllisSGCoxDA. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231.
18.
SousaJECostaMAAbizaidA. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111:2326–2329.
19.
TepeGZellerTAlbrechtT. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.
20.
WerkMLangnerSReinkensmeierB. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.
21.
KimS-JMasakiTLeypoldtJK. Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. J Lab Clin Med. 2004;144:156–162.
22.
MasakiTRathiRZentnerG. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. 2004;66:2061–2069.
23.
KellyBMelhemMZhangJ. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant. 2006;21:2425–2431.
24.
KatsanosKKarnabatidisDKitrouP. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther. 2012;19:263–272.
25.
AxelDIKunertWGöggelmannC. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636–645.
26.
WiskirchenJSchöberWSchartN. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39:565–571.
27.
RowinskyEKDonehowerRC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–1014.
28.
KovalikECNewmanGESuhockiP. Correction of central venous stenoses: use of angioplasty and vascular Wallstents. Kidney Int. 1994;45:1177–1181.
29.
QuinnSFSchumanESDemlowTA. Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results. J Vasc Interv Radiol. 1995;6:851–855.
30.
DammersRde HaanMWPlankenNR. Central vein obstruction in hemodialysis patients: results of radiological and surgical intervention. Eur J Vasc Endovasc Surg. 2003;26:317–321.
31.
SurowiecSMFegleyAJTanskiWJ. Endovascular management of central venous stenoses in the hemodialysis patient: results of percutaneous therapy. Vasc Endovascular Surg. 2004;38:349–354.
32.
BakkenAMProtackCDSaadWE. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. J Vasc Surg. 2007;45:776–783.
33.
AytekinCBoyvatFYağmurdurMC. Endovascular stent placement in the treatment of upper extremity central venous obstruction in hemodialysis patients. Eur J Radiol. 2004;49:81–85.
34.
HaagePVorwerkDPirothW. Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Radiology. 1999;212:175–180.
35.
KunduSModabberMYouJM. Use of PTFE stent grafts for hemodialysis-related central venous occlusions: intermediate-term results. Cardiovasc Intervent Radiol. 2011;34:949–957.
36.
JonesRGWillisAPJonesC. Long-term results of stent-graft placement to treat central venous stenosis and occlusion in hemodialysis patients with arteriovenous fistulas. J Vasc Interv Radiol. 2011;22:1240–1245.
37.
Anaya-AyalaJESmolockCJColvardBD. Efficacy of covered stent placement for central venous occlusive disease in hemodialysis patients. J Vasc Surg. 2011;54:754–759.
38.
PatanèDGiuffridaSMoraleW. Drug-eluting balloon for the treatment of failing hemodialytic radiocephalic arteriovenous fistulas: our experience in the treatment of juxta-anastomotic stenoses. J Vasc Access. 2014;15:338-343.
